Related Experiment Video
Updated: May 25, 2025

08:20
In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
Published on: May 1, 2020
6.7K
Causal Association Between Inflammatory Factors and Hypertrophic Scar: A Two-Sample Mendelian Randomization Study
Yanqi Li1, Yankun Zhang2, Wanchao Wang1
1Department of Plastic Surgery, Emergency General Hospital/National Research Center for Emergency Medicine, Beijing, China.
Journal of Cosmetic Dermatology
|February 27, 2025
Summary
This study investigated inflammatory factors in hypertrophic scar formation. Chemokine (C-C motif) ligand 27 (CTACK) showed a potential causal link to hypertrophic scars, suggesting new therapeutic targets.
Area of Science:
- Genetics
- Immunology
- Dermatology
Background:
- Hypertrophic scars arise from dysregulated healing post-skin injury.
- Inflammatory factors play a role in abnormal scar development.
Purpose of the Study:
- To investigate the causal relationship between specific inflammatory factors and hypertrophic scar risk.
- To identify potential biomarkers and therapeutic targets for hypertrophic scarring.
Main Methods:
- Utilized Mendelian randomization (MR) analysis with genetic data from the FINN cohort.
- Assessed eight inflammatory factors: IL-1β, IL-1Rrp, MCP1, RANTES/CCL5, TNFα, IL-8, IL-18, and CTACK/CCL27.
- Employed IVW, MR-Egger, weighted median, and weighted mode methods, with sensitivity analyses for robustness.
Main Results:
- A significant causal association was found between CTACK/CCL27 and hypertrophic scars (OR 1.21, p=0.01) via IVW, though not consistently across all MR methods.
- No significant causal links were observed for other assessed inflammatory factors.
- Sensitivity analyses indicated minimal horizontal pleiotropy, with no significant association for RANTES/CCL5 after outlier removal.
Conclusions:
- Mendelian randomization analysis supports a causal role for CTACK/CCL27 in hypertrophic scar development.
- Findings enhance understanding of scar pathogenesis and suggest CTACK/CCL27 as a potential therapeutic target.

